Arcutis Biotherapeutics, Inc.

Symbol: ARQT

NASDAQ

8.02

USD

Market price today

  • -2.8364

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 926.51M

    MRK Cap

  • 0.00%

    DIV Yield

Arcutis Biotherapeutics, Inc. (ARQT) Financial Statements

On the chart you can see the default numbers in dynamics for Arcutis Biotherapeutics, Inc. (ARQT). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Arcutis Biotherapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

balance-sheet.row.cash-and-short-term-investments

0272.8409.6387.1
284.4
101.3
50.9
3.4

balance-sheet.row.short-term-investments

0183.5355.9290.6
219.4
37.9
11.5
0

balance-sheet.row.net-receivables

025.88.50.4
0.5
0
0
0

balance-sheet.row.inventory

013.17.51.2
-0.5
0
0
0

balance-sheet.row.other-current-assets

018.710.614.2
8.4
5.2
0.2
0.4

balance-sheet.row.total-current-assets

0330.4437.4402.8
292.8
106.5
51.1
3.8

balance-sheet.row.property-plant-equipment-net

03.94.65.3
5.4
0.5
0
0

balance-sheet.row.goodwill

0000
0
0
0
0

balance-sheet.row.intangible-assets

06.47.20
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

06.47.20
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0

balance-sheet.row.other-non-current-assets

00.60.10.1
0.1
0
0
0

balance-sheet.row.total-non-current-assets

010.911.95.4
5.4
0.5
0
0

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

0341.4449.3408.2
298.3
107
51.1
3.8

balance-sheet.row.account-payables

0128.87.4
7.1
1.4
1.8
0.5

balance-sheet.row.short-term-debt

00.70.70.4
0
0.2
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0

balance-sheet.row.long-term-debt-total

0201.8201.977.1
5
0.1
0
0

Deferred Revenue Non Current

0000
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

033.928.325.5
15.5
3.7
0.9
0.2

balance-sheet.row.total-non-current-liabilities

0206201.977.1
5
166.8
72.4
8.1

balance-sheet.row.other-liabilities

0000
0
0
0
0

balance-sheet.row.capital-lease-obligations

03.44.85.2
5
0.3
0
0

balance-sheet.row.total-liab

0252.7239.7110.5
27.6
172
75.1
8.8

balance-sheet.row.preferred-stock

0000
298.3
166.5
0
0

balance-sheet.row.common-stock

0000
0
0
0
0

balance-sheet.row.retained-earnings

0-981.9-719.8-408.3
-201.9
-66.3
-24.3
-5

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-1.1-0.3
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

01070.6930.4706.2
174.3
-165.2
0.3
0

balance-sheet.row.total-stockholders-equity

088.7209.6297.7
270.6
-65
-24
-5

balance-sheet.row.total-liabilities-and-stockholders-equity

0341.4449.3408.2
298.3
107
51.1
3.8

balance-sheet.row.minority-interest

0000
0
0
0
0

balance-sheet.row.total-equity

088.7209.6297.7
270.6
-65
-24
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-

Total Investments

0183.5355.9290.6
219.4
37.9
11.5
0

balance-sheet.row.total-debt

0205.9202.577.6
5
0.3
0
0

balance-sheet.row.net-debt

0116.6148.9-18.9
-60.1
-63
-39.4
-3.4

Cash Flow Statement

The financial landscape of Arcutis Biotherapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

cash-flows.row.net-income

0-262.1-311.5-206.4
-135.7
-42
-19.3
-5

cash-flows.row.depreciation-and-amortization

01.90.90.5
0.1
0.2
0
0

cash-flows.row.deferred-income-tax

019.803.5
0.1
0
0
0

cash-flows.row.stock-based-compensation

038.832.723.9
7.9
0.8
0.2
0

cash-flows.row.change-in-working-capital

0-23.5-10.23.6
14.1
-1.5
2.1
0.3

cash-flows.row.account-receivables

0-17.3-8.50
0
0
0
0

cash-flows.row.inventory

0-5.6-7.50
0
0
0
0

cash-flows.row.account-payables

03.21.60.2
5.7
-0.5
1.3
0.5

cash-flows.row.other-working-capital

0-3.74.23.4
8.5
-1
0.8
-0.3

cash-flows.row.other-non-cash-items

0-21.930.30.3
0.3
-0.4
2.9
0.9

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-0.4-23.3-1
-0.3
-0.3
0
0

cash-flows.row.acquisitions-net

0022.975
181.5
26
0
0

cash-flows.row.purchases-of-investments

0-225.8-415.4-292.5
-279.1
-60.8
-11.5
0

cash-flows.row.sales-maturities-of-investments

0406.5351.5217.6
97.6
34.8
0
0

cash-flows.row.other-investing-activites

00-22.9-75
-181.5
-26
0
0

cash-flows.row.net-cash-used-for-investing-activites

0180.2-87.2-76
-181.8
-26.3
-11.5
0

cash-flows.row.debt-repayment

00-122.8-72.3
0
0
0
0

cash-flows.row.common-stock-issued

0101.3176207.5
297
94.2
0
0

cash-flows.row.common-stock-repurchased

0012.50.8
0.6
0
0
0

cash-flows.row.dividends-paid

00-122.8-72.3
0
0
0
0

cash-flows.row.other-financing-activites

05.6358.9218.3
0.5
-1.1
61.6
7.1

cash-flows.row.net-cash-used-provided-by-financing-activities

0101.3301.8281.9
298.1
93.1
61.6
7.1

cash-flows.row.effect-of-forex-changes-on-cash

0-0.100
0
0
0
0

cash-flows.row.net-change-in-cash

034.4-43.131.4
3.3
23.9
36
3.3

cash-flows.row.cash-at-end-of-period

089.354.998
66.6
63.3
39.4
3.4

cash-flows.row.cash-at-beginning-of-period

054.99866.6
63.3
39.4
3.4
0.1

cash-flows.row.operating-cash-flow

0-247.1-257.7-174.6
-113
-42.8
-14.1
-3.8

cash-flows.row.capital-expenditure

0-0.4-23.3-1
-0.3
-0.3
0
0

cash-flows.row.free-cash-flow

0-247.5-281-175.6
-113.4
-43.1
-14.1
-3.8

Income Statement Row

Arcutis Biotherapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of ARQT is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

income-statement-row.row.total-revenue

059.63.70
0
0
0
0

income-statement-row.row.cost-of-revenue

06.10.80.8
0.5
0.2
0
0

income-statement-row.row.gross-profit

053.52.9-0.8
-0.5
-0.2
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

011.85.80.2
1
1.1
0.5
-0.9

income-statement-row.row.operating-expenses

0294.6304.6206.5
136.6
43.1
19.7
4.1

income-statement-row.row.cost-and-expenses

0300.7305.3206.5
136.6
43.1
19.7
4.1

income-statement-row.row.interest-income

009.80.2
1
1.1
0
0

income-statement-row.row.interest-expense

029.715.70
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-17.9-9.80.2
1
1.1
0.5
-0.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

011.85.80.2
1
1.1
0.5
-0.9

income-statement-row.row.total-operating-expenses

0-17.9-9.80.2
1
1.1
0.5
-0.9

income-statement-row.row.interest-expense

029.715.70
0
0
0
0

income-statement-row.row.depreciation-and-amortization

01.95.80.5
0.1
0.2
0.5
0

income-statement-row.row.ebitda-caps

0---
-
-
-
-

income-statement-row.row.operating-income

0-241.1-301.6-206.5
-136.6
-43.1
-19.7
-4.1

income-statement-row.row.income-before-tax

0-259-311.5-206.4
-135.7
-42
-19.3
-5

income-statement-row.row.income-tax-expense

03.19.8-0.5
0
0
-0.5
0

income-statement-row.row.net-income

0-262.1-321.3-205.9
-135.7
-42
-19.3
-5

Frequently Asked Question

What is Arcutis Biotherapeutics, Inc. (ARQT) total assets?

Arcutis Biotherapeutics, Inc. (ARQT) total assets is 341365000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.913.

What is company free cash flow?

The free cash flow is -2.673.

What is enterprise net profit margin?

The net profit margin is -4.392.

What is firm total revenue?

The total revenue is -4.045.

What is Arcutis Biotherapeutics, Inc. (ARQT) net profit (net income)?

The net profit (net income) is -262140000.000.

What is firm total debt?

The total debt is 205916000.000.

What is operating expences number?

The operating expences are 294589000.000.

What is company cash figure?

Enretprise cash is 0.000.